Replimune Group (NASDAQ:REPL) Rating Lowered to Neutral at Piper Sandler

Replimune Group (NASDAQ:REPL) was downgraded by Piper Sandler from an “overweight” rating to a “neutral” rating in a note issued to investors on Friday, MarketBeat.com reports. They currently have a $4.00 target price on the stock. Piper Sandler’s target price suggests a potential downside of 16.16% from the company’s current price.

Several other equities research analysts have also recently commented on the stock. Wedbush boosted their price target on shares of Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.75.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $4.77 on Friday. Replimune Group has a fifty-two week low of $2.68 and a fifty-two week high of $13.24. The firm’s 50-day simple moving average is $7.51 and its 200 day simple moving average is $7.93. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. The stock has a market cap of $393.94 million, a P/E ratio of -1.39 and a beta of 0.74.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.08. Equities analysts expect that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total value of $52,065.00. Following the sale, the insider directly owned 151,588 shares in the company, valued at approximately $1,214,219.88. The trade was a 4.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently bought and sold shares of the business. International Assets Investment Management LLC acquired a new stake in Replimune Group during the 4th quarter worth about $29,000. CWM LLC raised its holdings in Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares during the period. BNP Paribas Financial Markets raised its holdings in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after buying an additional 1,879 shares during the period. Raymond James Financial Inc. acquired a new stake in Replimune Group during the 2nd quarter worth about $69,000. Finally, Russell Investments Group Ltd. raised its holdings in Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the period. 92.53% of the stock is currently owned by institutional investors.

Key Replimune Group News

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Trading activity and market mechanics: REPL was subject to multiple intraday halts and LULD pauses as news flowed, which amplified volatility and could have increased selling pressure.
• Negative Sentiment: FDA rejection — The U.S. Food and Drug Administration declined to approve Replimune’s drug for advanced skin cancer (second rejection), a direct hit to the company’s key commercial and valuation thesis. US FDA declines to approve Replimune’s drug for advanced skin cancer
• Negative Sentiment: Broad media coverage of the second FDA rejection reinforced negative investor sentiment and drove selling. (Coverage examples: Stat, MarketWatch, WSJ.) Replimune skin cancer drug that became FDA flashpoint is rejected again
• Negative Sentiment: Analyst downgrade — Piper Sandler cut REPL from “Overweight” to “Neutral” and set a $4.00 price target (about a mid‑single‑digit percentage downside vs. the traded level), signaling weaker near‑term conviction from sell‑side analysts and pressuring the stock.
• Negative Sentiment: Bearish positioning & insider activity — Unusual options activity showed a notable uptick in put buying ahead of the decision, and reports of insider selling were published earlier in the week; both are bearish indicators for near‑term sentiment. Replimune insider selling report

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.